At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 38 enrolled
Drug / intervention
Guselkumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
In Brief
A Phase 3 clinical trial evaluating Guselkumab for Crohns Disease. Completed, enrolled 38 participants across 25 sites.
Detailed Summary
The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohns Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMay 2020
Enrollment StartJun 2020
Primary CompletionFeb 2024
Study CompletionSep 2025
TodayJul 2026
First PostedMay 21, 2020
Enrollment StartJun 10, 2020
Primary CompletionFeb 29, 2024
Study CompletionSep 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 6.1 years ago
Interventions
Guselkumabdrug
Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.